195.04 0.00 (0.00%)
After hours: 5:06PM EDT
|Bid||194.95 x 800|
|Ask||195.09 x 800|
|Day's Range||193.59 - 196.83|
|52 Week Range||166.30 - 211.90|
|Beta (3Y Monthly)||0.80|
|PE Ratio (TTM)||15.49|
|Earnings Date||Oct 28, 2019 - Nov 1, 2019|
|Forward Dividend & Yield||5.80 (2.95%)|
|1y Target Est||214.84|
Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.
New Data Show Clinical Responses in Colorectal and Appendiceal Cancer Patients Treated With AMG 510 Two Late-Breaking Abstracts With Data Highlighting IMLYGIC® (Talimogene Laherparepvec) for Neoadjuvant ...
The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.
- Q2 2019 share repurchases were $164.5 billion - 20.1% lower than Q1 2019, 13.7% lower than Q2 2018, and 26.2% lower than the record Q4 2018. - Apple continues to lead, spending $18.2 billion - down from ...
Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.
THOUSAND OAKS, Calif. , Sept. 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. British Summer Time on Wednesday, ...
THOUSAND OAKS, Calif., Sept. 13, 2019 /PRNewswire/ -- Amgen (AMGN) today announced the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX® (daratumumab) (KdD) compared to KYPROLIS and dexamethasone alone (Kd) met its primary endpoint of progression-free survival (PFS).
Shares of Amgen are on an upswing after winning a patent battle over its drug Enbrel against Novartis subsidiary Sandoz. Is it time to buy shares of the massive biotech company?
Jaclyn Schuler’s role as a leader at Amgen in Tampa is to motivate her teams to deliver value and impact the bottom line.
The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.
THOUSAND OAKS, Calif., Sept. 12, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that new data from its oncology portfolio and pipeline will be presented at the 17th International Myeloma Workshop (IMW) 2019 in Boston, Sept. 12-15, 2019. Data featured from Amgen's hematology franchise will include oral presentations from Phase 1 studies of AMG 420, the anti-B-cell maturation antigen (BCMA) bispecific T cell engager (BiTE®) and AMG 176, the MCL-1 inhibitor in patients with relapsed or refractory multiple myeloma. Other data being presented will include safety and efficacy results of once-weekly dosing of KYPROLIS® (carfilzomib) in different regimens across several patient populations, and Phase 3 results from the first KYPROLIS trial to be conducted in China.
REYKJAVIK, Iceland , Sept. 11, 2019 /CNW/ -- deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare companies to undertake whole genome sequencing of UK Biobank participants. The project will allow the complete sequencing of the genetic code of all 500,000 participants in the UK Biobank. The UK Biobank is an extraordinary resource for medical research that Great Britain has built over the past 15 years.
Shares of pharmaceutical companies toppled Tuesday on reports the House of Representatives will release a plan that allows the federal government to negotiate drug prices in Medicare.